If you ever wondered whether appetite reducers can really help you lose weight, the study results are in!
InQpharm, the company that brought plant-based, clinically tested bmiSMART to the US, spends millions in clinical research to test the effectiveness and safety of its weight loss products. The latest placebo-controlled, double-blind randomized studies has now been published in a peer-reviewed academic journal--the gold stat of clinical research.
Citation: Advancement in Medicinal Plant Research Vol. 4(3), pp. 73-82, July 2016 ISSN: 2354-2152.
A total of 119 overweight and obese male and female subjects (BMI 25–35 kg/m2) between 18 and 65 years of age were enrolled in the randomized, double-blind, placebo-controlled study. After a 2-week lead-in phase, subjects took either Redusure or a placebo 30–60 minutes before breakfast, lunch and dinner for 12 weeks. All subjects were instructed to maintain a similar nutritionally balanced, mildly hypo-caloric diet composed of 50% carbohydrate, 30% fat and 20% protein. At the conclusion of the trial, individuals receiving Redusure showed a mean body weight reduction of 3.53 kg (7.78 lbs.) compared to 0.14 kg (0.30 lbs.) in the placebo group. Food cravings and satiety were also measured and participants who received Redusure reported a moderate to strong feeling of satiety at 94.7%.
Significant reduction in mean body weight was observed as early as week 4, with a loss of 1.01 kg (2.23 lbs.) for the Redusure group compared to 0.25 kg (0.55 lbs.) for placebo. Additionally, no adverse events were reported during the trial and no clinically significant changes were observed in blood profiles or blood pressure. Of note, the placebo group actually gained back some of the weight lost in the first four weeks by the end of the 12-week period.